Discovery on Target 2017 Highlights
Dear Members of the Discovery on Target Community,
The 15th Annual Discovery on Target 2017 drew record attendance this September 25-29, 2017 with more than 1,300 international participants from 25 countries networking and discussing current and emerging ‘hot’ drug targets for the pharmaceutical industry.
The Exhibit Hall featured 50+ companies with novel technologies and solutions, including sponsored talks by leading technology and service providers showcasing new offerings. Attendees also viewed 110 posters featuring cutting-edge, ongoing research by students, academia and industry.
The event included 340+ expert speakers, 17 conference tracks, 2 training seminars, 7 symposia, and 7 interactive courses. New coverage included immunomodulatory small molecules, targeting tumor myeloid cells, microbiome in immuno-oncology, autophagy, fibrosis, constrained peptides and macrocyclics, oligonucleotide therapeutics, HBV, CNS targets, lead generation and target identification strategies.
Thank you for your continued support of Discovery on Target. Present your research at the 16th Annual Discovery on Target, September 25-28, 2018 at our new venue, the Sheraton Boston.
2017 Testimonials
“I found this event to be extraordinarily helpful in forming a network with other scientists involved in hit seeking and hit triage. I was also able to connect with vendors offering products and services that can advance the research of my team (both in cost and efficiency)."
Research Investigator II, Bristol-Myers Squibb
“Excellent meeting to help academic researchers keep up with industrial best practices.”
Research Associate Professor, Medicinal Chemistry, The University of Minnesota
“High quality scientific presentations; excellent speakers. Well organized and stays on schedule. Introduced my company to several NASH pharma companies."
Director, Business Development, Qualyst Transporter Solutions LLC
“This meeting is getting bigger and better every year.”
Director, Medicinal Chemistry, Array Biopharma
“I really enjoyed the NK meeting ... I attend a number of similar conferences but I like this one as there is a healthy mix of academia and biotech/business and you even bring in international speakers. Boston is a great location.”
Vice President, Research & Development, NantKwest, Inc.
“You’ve had a number of very impressive speakers on the subject of ‘conformational states for GPCRs relevant to ligand binding’ in the last couple of conferences.”
Senior Scientist, Biophysical Chemistry, Takeda
“Very comprehensive program with new advances in the field both technically and scientifically presented. Presentations also covered multiple therapeutic areas and lessons learned from different GPCRs.”
Principal Scientist, Bristol-Myers Squibb
“I found the session on constrained peptides and macrocycles full of useful information and new contacts.”
Director, Assay Development and Screening Technologies, National Center for Advancing Translational Sciences (NCATS), NIH
“Macrocycle symposium provided me with a good overview of [the] state of the art on PROTACs in [the] Ubiquitin conference track. Also good information on other Ubiquitin-related drug discovery.”
Senior Principal Scientist, Janssen R&D
“Many thanks for the opportunity to speak in Boston at DOT this year. I enjoyed all the conferences organized by CHI and think they provide a very good forum.”
Postdoctoral Fellow, AstraZeneca Gothenburg
“DOT is a unique week that looks at early discovery to clinical POC.”
CMO & Executive Vice President, R&D, Madrigal Pharmaceuticals